Blog

Segal Trials and Psychedelic Research in South Florida

After 24 years… and over 1,200 trials… across more than 75 therapies… Segal Trials is pushing into a new area of expertise—and helping pave the way for psychedelic clinical research. The company was recently selected as the first research site to conduct a Phase 2 study to test the efficacy and safety of LSD as…

Psychedelic Sector News – Weekly Extractions: August 5, 2022

It was another exciting week in the psychedelics industry. This week, Psychedelic Invest’s own Adam Tubero highlights the three biggest events of the week. The entire video can be found below. In addition, don’t forget that each Weekly Extraction is also listed underneath the video. Extraction #1: Aaron Rodgers Attributes His Success to Ayahuasca During…

MindMed

MindMed Board of Directors Approves Reverse Share Split

Mind Medicine Inc. (NASDAQ: MNMD | NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that its Board of Directors has approved a ratio of 1-for-15 reverse share split of its common shares. As a result of the reverse share split, there will be approximately 28.4 million shares…

Psychedelics Could Disrupt the $42 Billion a Year Rehab Industry

Many eager investors have been flocking to psychedelics with the “gold rush” mentality over the past few years. Another industry that has seen this pattern over the past decade is rehab. The burgeoning psychedelic treatment space has a lot of cross-over with addiction treatment and rehabilitation.  In 2020, drug and alcohol addiction treatment brought in…